For the fourth quarter ended December 31, 2025, argenx generated total operating income of 1322155000 and product net sales of 1285711000, primarily driven by VYVGART. Operating profit reached 367611000 and profit for the period was 532950000, with diluted EPS of 8.02.

argenx delivered robust revenue growth in Q1 2025 with product net sales reaching $790 million and reported a net profit of $169 million, reversing a loss from the previous year. Strong momentum in VYVGART launches and expansion supported commercial performance.

Argenx achieved Q4 2024 revenue of $761.2 million, driven by strong VYVGART product sales. Net income reached $774.2 million, reflecting a significant improvement from the prior year’s loss. Diluted EPS was $11.79, while adjusted EPS was $0.93. The company benefited from a one-time tax gain of $725 million, contributing to profitability.